BTS is a potent and selective inhibitor of Ca2+-stimulated myosin S1 ATPase with IC50 value of ~5 µM.

Aficamten is a cardiac myosin allosteric inhibitor.

ML 9 a is myosin light chain kinase (MLCK) inhibitor. ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt pathway and the autophagy.

Omecamtiv mecarbil is a selective sarcomere-directed cardiac myosin activator with an EC50 of 0.6 μM.

(-)-Blebbistatin is a selective cell-permeable inhibitor of non-muscle myosin II ATPases and the active enantiomer of (+)-blebbistatin. It rapidly and reversibly inhibits Mg-ATPase activity and in vitro motility of non-muscle myosin IIA and IIB for several species (IC50 = 0.5-5 µM), while poorly inhibiting smooth muscle myosin (IC50 = 80 µM​).

MYK-461 is a myosin inhibitor potentially for the treatment of hypertrophic cardiomyopathy, and can reduce contractility by decreasing the adenosine triphosphatase activity of the cardiac myosin heavy chain.

ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.